Bausch Health Reports Strong Third Quarter 2024 Results

Bausch Health Companies Inc. has achieved its sixth consecutive quarter of year-over-year growth in revenue and adjusted EBITDA. For the third quarter of 2024, the company reported consolidated revenues of $2.51 billion, reflecting a 12% increase from the previous year. Organic growth stood at 9%. However, the company incurred a GAAP net loss of $85 million. Adjusted EBITDA reached $909 million, a 10% increase over the same quarter in 2023.

The segments showed varied performance. Notably, Bausch + Lomb generated $1,196 million in revenues, a 19% rise compared to 2023. Solta Medical experienced a 35% increase, driven by growth in South Korea and China. Salix and International segments grew by 5% and 8% organically. The company has raised its full-year 2024 guidance.

Bausch Health remains committed to advancing its R&D pipeline with the launch of CABTREO® in Canada and progressing several other initiatives. It continues efforts to manage its debt profile and strengthen its balance sheet.